首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2377篇
  免费   81篇
  国内免费   9篇
耳鼻咽喉   16篇
儿科学   53篇
妇产科学   12篇
基础医学   279篇
口腔科学   8篇
临床医学   119篇
内科学   544篇
皮肤病学   7篇
神经病学   254篇
特种医学   49篇
外科学   595篇
综合类   12篇
预防医学   44篇
眼科学   127篇
药学   152篇
中国医学   3篇
肿瘤学   193篇
  2022年   10篇
  2021年   24篇
  2020年   15篇
  2019年   18篇
  2018年   29篇
  2017年   23篇
  2016年   30篇
  2015年   34篇
  2014年   46篇
  2013年   71篇
  2012年   101篇
  2011年   118篇
  2010年   69篇
  2009年   59篇
  2008年   119篇
  2007年   153篇
  2006年   156篇
  2005年   147篇
  2004年   163篇
  2003年   158篇
  2002年   177篇
  2001年   34篇
  2000年   67篇
  1999年   46篇
  1998年   54篇
  1997年   57篇
  1996年   53篇
  1995年   40篇
  1994年   38篇
  1993年   30篇
  1992年   32篇
  1991年   28篇
  1990年   32篇
  1989年   31篇
  1988年   39篇
  1987年   14篇
  1986年   16篇
  1985年   16篇
  1984年   15篇
  1983年   12篇
  1982年   9篇
  1981年   12篇
  1980年   5篇
  1979年   10篇
  1978年   7篇
  1977年   7篇
  1976年   6篇
  1972年   4篇
  1970年   6篇
  1968年   4篇
排序方式: 共有2467条查询结果,搜索用时 15 毫秒
1.
The adrenal cortex gives rise to a biologically heterogenous group of neoplasms, each with a distinct morphology, antigen expression and molecular profile. Adrenal cortical adenomas have excellent prognosis and are usually cured by surgical resection alone, while adrenal cortical carcinomas are very aggressive tumors with a poor prognosis regardless of therapy. These tumors are rare and often challenging for a pathologist to diagnose, as significant overlap exists between benign and malignant lesions in some cases. In this review, we attempt to summarize most important histologic and clinical features of adrenal cortical adenomas and carcinomas, clarify the use of different grading systems, the use of special stains and the differential diagnosis for practicing pathologists. Most relevant hereditary syndromes associated with adrenal cortical tumors are listed. Updates in molecular alterations in adrenal cortical neoplasms and hyperplastic diseases as well as their clinical significance and potential therapeutic implications are also discussed.  相似文献   
2.
3.
The present study was undertaken to examine whether the second generation antibiotic drug minocycline attenuates behavioral changes (eg, acute hyperlocomotion and prepulse inhibition (PPI) deficits) in mice after the administration of the N-methyl-D-aspartate (NMDA) receptor antagonist (+)-MK-801 (dizocilpine). Dizocilpine (0.1 mg/kg)-induced hyperlocomotion was significantly attenuated by pretreatment with minocycline (40 mg/kg). Furthermore, the PPI deficits after a single administration of dizocilpine (0.1 mg/kg) were attenuated by pretreatment with minocycline (10, 20, or 40 mg/kg), in a dose-dependent manner. Moreover, in vivo microdialysis study in the free-moving mice revealed that pretreatment with minocycline (40 mg/kg, i.p.) significantly attenuated the increase of extracellular dopamine (DA) levels in the frontal cortex and striatum after administration of dizocilpine (0.1 mg/kg), suggesting that the inhibition of dizocilpine-induced DA release by minocycline may, at least in part, be implicated in the mechanism of action of minocycline with respect to dizocilpine-induced behavioral changes in mice. These findings suggest that minocycline could attenuate behavioral changes in mice after the administration of the NMDA receptor antagonist dizocilpine. Therefore, it is possible that minocycline would be a potential therapeutic drug for schizophrenia.  相似文献   
4.
Tissue distribution and excretion of hexabromobenzene (HBB) and some metabolites were studied in male Wistar rats administered a single oral dosage of HBB.Most of the HBB dosage was absorbed by the intestinal tract and it was rapidly metabolized and distributed throughout the body as the debrominated metabolites, pentabromobenzene (PeBB), tetrabromobenzene (TeBB) and tribromobenzene (TrBB). The time courses of HBB, PeBB and TeBB concentrations in the tissues were roughly classified into several types, and debromination of HBB was found to take place stepwise.The reductive debromination of HBB occurs by metabolic enzymes in the liver rather than microbes in the intestine.  相似文献   
5.
6.
7.
At present, approximately 1 million patients are on chronic hemodialysis in the world. Some patients have been dialyzed for more than 20 years. However, chronic hemodialysis produces a new type of disease known as chronic hemodialysis syndrome. Procedurally induced immunomodulation may be the cause of this syndrome. Hematological changes imposed by this extracorporeal circulation for hemodialysis are discussed in this article. A comparison with procedurally induced immunomodulation by apheresis procedures is also provided. This repeated exposure of the blood-to-blood purification device with a large foreign surface produces quite substantial immunological effects to the patient. Thus, further studies were necessary to analyze more clearly the adaptation mechanism of the human defense system. On the basis of these studies, the following conclusion could be derived. Typically, Stage 1, human adaptation to the implanted or applied man-made machine, would be 48 h and could be divided into 3 phases. They would be Phase I (15-30 min) leukocyte storage, Phase II (2-24 h) leukocyte release, and Phase III (24-48 h) completion of the proper leukocyte response. To adapt hematologically in 48 h, the patient may experience 3 phases of adaptation reactions. When patients are subjected to extracorporeal circulation, the immunosuppressive state of hemodialysis is hypothesized through these studies.  相似文献   
8.
Abstract: Pyridoxalated-hemoglobin-polyoxyethylene conjugate (PHP), which is made from out-dated human red blood cells by two major chemical modifications, namely pyridoxalation and conjugation with polyoxyethylene (POE), is currently under development as a physiological oxygen carrier. This study assessed the effects of PHP-88 solution, which contains 8% (wt/vol) each of hemoglobin (Hb) and maltose, on renal function when it was infused 3 times every other day into the intact circulation of 8 dogs (5 dogs for the PHP group and 3 for the control group; 20 ml/kg for the first infusion, and 10 ml/kg each for the second and third infusions, at the rate of 2.5 ml/h/kg). Serial determinations of glomerular filtration rate (GFR) and renal plasma flow (RPF) were carried out pre- and postinfusion for up to 3 months along with measurements of blood and urine analyses, urine output rate, fractional excretion of sodium (FES), and free water clearance (CH2O). The results showed that plasma colloid osmotic pressure (COP) elevated an average of 3.3 mm Hg (p = 0.0085), and GFR and RPF tended to increase by 13% (NS) and 38% (NS), respectively, immediately after the third infusion with PHP solution. Urine output rate increased during and after the infusion, and FES and CH2O also increased for 24 h after the infusion in both groups. Blood urea nitrogen, serum creatinine, and serum Na+ concentrations were not affected greatly by the infusions, but hematocrit was decreased by 8% in the PHP group, indicating approximately a 42% expansion of plasma volume. These changes were observed to return to their preinfusion levels by 1 week postinfusion. Renal histology of the PHP group obtained at 2 weeks postinfusion revealed vacuole formation in the proximal tubules which was not associated with any pathologic changes indicative of cell death or regeneration. In 4 out of 5 dogs at 3 months postinfusion (necropsy), the vacuoles were not present. Though urinary N-acetyl β-glucosaminidase (NAG) activity had significantly increased after infusion, it returned to the preinfusion level by 1 month postinfusion. No detrimental effect of vacuoles on the assessed renal tubular functions was confirmed in the present study. The result demonstrated that multiple infusions of PHP solutions were well tolerated in normal dogs, and the observed effects were conceived predominantly attributable to the physiological response of the kidneys to an oncotic load into the circulation, which produced plasma volume expansion.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号